Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com
As a family foundation and a public-interest foundation at the same time, the Fondation Bettencourt Schueller has chosen to “take talents to the top” to contribute to France’s success and influence.
To this end, the Foundation seeks, selects, supports and promotes women and men who are rethinking our future in three fields that make a tangible difference to the common good: life sciences, the arts and an inclusive society.
With a philanthropic mindset, the foundation takes action through prizes, donations, personalized support, effective communication and co-created initiatives.
Since the foundation was founded in 1987, it has awarded prizes to 620 laureates and supported more than 1,000 projects led by talented individuals, teams, associations and organizations.
For more information: www.fondationbs.org | Twitter: @Fondation_BS | Instagram: @fondationbettencourtschueller | Facebook: @BettencourtSchuellerFoundation | #TalentFondationBettencourt
The mission of the “Fondation de l’Académie des technologies” is to improve the public’s understanding of the interest of technologies and their uses, to promote the teaching of technologies in the training of young people, to enhance the contribution of technologies to the development of France, and to initiate and participate in demonstrators for the introduction or adaptation of technologies.
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.